Cargando…

Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy

IgA nephropathy is the most common primary glomerulonephritis and one of the leading causes of end-stage renal disease. We performed a randomized, controlled, prospective, open-label trial to determine whether leflunomide combined with low-dose corticosteroid is safe and effective for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Lulin, Wang, Qin, Cao, Liou, Zhou, Wenyan, Yuan, Jiangzi, Zhang, Minfang, Che, Xiajing, Mou, Shan, Fang, Wei, Gu, Leyi, Zhu, Mingli, Wang, Ling, Yu, Zanzhe, Qian, Jiaqi, Ni, Zhaohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564655/ https://www.ncbi.nlm.nih.gov/pubmed/28415636 http://dx.doi.org/10.18632/oncotarget.16468

Ejemplares similares

Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
por: Li, Yebei, et al.
Publicado: (2021)

Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial
por: Ni, Zhaohui, et al.
Publicado: (2021)

Efficacy and safety of leflunomide combined with corticosteroids for the treatment of IgA nephropathy: a Meta-analysis of randomized controlled trials
por: Lv, Guangxin, et al.
Publicado: (2022)

The effectiveness and safety of full-dose versus half-dose corticosteroid plus renin-angiotensin system blockers for IgA nephropathy
por: Wang, Li, et al.
Publicado: (2019)

Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission
por: Ni, Zhaohui, et al.
Publicado: (2014)

Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study
por: Yuan, Yanhong, et al.
Publicado: (2015)

A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study
por: Chen, Shasha, et al.
Publicado: (2018)

Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy
por: Ye, Young-Min, et al.
Publicado: (2015)

C4d as a Screening Tool and an Independent Predictor of Clinical Outcomes in Lupus Nephritis and IgA Nephropathy
por: Yang, Xiaoqian, et al.
Publicado: (2022)

Association of Relapse with Renal Outcomes under the Current Therapy Regimen for IgA Nephropathy: A Multi-Center Study
por: Yuan, Yanhong, et al.
Publicado: (2015)

Comparative analysis between the safety and efficacy of oral corticosteroids versus corticosteroids pulse therapies in IgA nephropathy
por: Wang, Yu, et al.
Publicado: (2023)

Serum IL-18 Is Closely Associated with Renal Tubulointerstitial Injury and Predicts Renal Prognosis in IgA Nephropathy
por: Shi, Beili, et al.
Publicado: (2012)

Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage
por: Pozzi, Claudio, et al.
Publicado: (2012)

Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy
por: Sarcina, Cristina, et al.
Publicado: (2016)

Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
por: Cai, Qingqing, et al.
Publicado: (2017)

Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy
por: Shang, Shunlai, et al.
Publicado: (2022)

Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors
por: Moriyama, Takahito, et al.
Publicado: (2020)

Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
por: Pei, Gaiqin, et al.
Publicado: (2020)

Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison
por: Ismail, Gener, et al.
Publicado: (2020)

Albumin-to-fibrinogen ratio is an independent predictor of corticosteroid response and prognosis in patients with IgA nephropathy
por: Zhang, Yu, et al.
Publicado: (2023)

Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe Covid-19?
por: Cordeiro Veiga, Viviane, et al.
Publicado: (2022)

Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients
por: Mandadi, Subhadra, et al.
Publicado: (2022)

Oral dosing for antenatal corticosteroids in the Rhesus macaque
por: Schmidt, Augusto F., et al.
Publicado: (2019)

Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study
por: Yang, Ya-zi, et al.
Publicado: (2019)

IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report
por: Watanabe, Shota, et al.
Publicado: (2022)

The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study
por: Liang, Mengjun, et al.
Publicado: (2022)

Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy
por: Kawamura, Tetsuya, et al.
Publicado: (2023)

Leflunomide as a Corticosteroid-Sparing Agent in Giant Cell Arteritis and Polymyalgia Rheumatica: A Case Series
por: Diamantopoulos, Andreas P., et al.
Publicado: (2013)

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
por: Miyagawa, Ippei, et al.
Publicado: (2019)

Chlorhexidine Monotherapy with Adjunctive Topical Corticosteroids for Acanthamoeba Keratitis
por: Rahimi, Firoozeh, et al.
Publicado: (2015)

High-Sensitivity C-Reactive Protein: An Independent Risk Factor for Left Ventricular Hypertrophy in Patients with Lupus Nephritis
por: Shi, Beili, et al.
Publicado: (2010)

Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata
por: Yeo, In Kwon, et al.
Publicado: (2015)

Yes-associated protein regulates podocyte cell cycle re-entry and dedifferentiation in adriamycin-induced nephropathy
por: Xie, Kewei, et al.
Publicado: (2019)

Inhaled corticosteroids: potency, dose equivalence and therapeutic index
por: Daley-Yates, Peter T
Publicado: (2015)

Perioperative “stress dose” of corticosteroid: Pharmacological and clinical perspective
por: Chilkoti, Geetanjali T., et al.
Publicado: (2019)

Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome
por: Christian, Martin T., et al.
Publicado: (2021)

Antenatal corticosteroids: a reappraisal of the drug formulation and dose
por: Jobe, Alan H., et al.
Publicado: (2020)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study
por: Si, Feng-Lei, et al.
Publicado: (2023)

Leflunomide therapy for IgA vasculitis with nephritis in children
por: Hou, Ling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4gdumqune5gp0mgb0qvub51977